Aligos Therapeutics (ALGS) investor relations material

Financial position and partnerships

• Cash, cash equivalents, and investments totaled $30.4M as of June 30, 2026, with projected runway through Q4 2026, excluding a $25M upfront payment received in Q3 from a Greater China license deal.

• Exclusive license agreement in Greater China with Amoytop Biotech for pevifoscorvir sodium includes $25M upfront and up to $420M in milestones, plus tiered royalties.

• Estimated $1B annual US market opportunity for HBV therapies, with significant global potential.

Development pipeline and clinical progress

• Pevifoscorvir sodium (CAM-E) is in Phase 2 for chronic HBV, with topline data expected in late Q3 2027; received FDA Fast Track Designation.

• ALG-170675 (ASO) is in Phase 1 in China, with first participant dosed in August 2026; preclinical data show improved efficacy and safety over competitors.

• Pevifoscorvir sodium demonstrated superior HBV DNA suppression compared to standard of care in Phase 1, with 100% of HBeAg- and 60% of HBeAg+ participants reaching LLOQ at week 48.

Market need and clinical rationale

• Chronic HBV infection affects 240M globally, with only 4.3% treated and over 1.1M HBV-related deaths in 2024; current therapies leave most patients at risk for progression.

• Standard of care NAs do not address all drivers of disease; functional cure rates remain low (~6-8% of all HBV patients).

• Pevifoscorvir sodium targets replication, integration, and reservoir, aiming to improve outcomes as monotherapy or in combination.